Novartis challenges loss of experts in spat with Pharmacor over generic Gilenya

Appeals 2022-03-28 3:25 pm By Christine Caulfield | Melbourne

Please login to bookmark

Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au